Precigen Inc (PGEN)
Precigen Inc. is a NASDAQ-listed common stock company in the healthcare sector focused on biotechnology. The company is a discovery and clinical-stage biopharmaceutical business developing gene and cell therapies that use precision technology for diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Its operations are organized into two segments, Biopharmaceuticals and Exemplar.
Precigen’s therapeutic platforms include AdenoVerse, which uses proprietary adenovectors to deliver therapeutic effectors, immunomodulators, and vaccine antigens, and UltraCAR-T, which is designed for chimeric antigen receptor T-cell therapies in cancer. The company is advancing a range of clinical programs built on these platforms, including PRGN-3005, PRGN-3006, PRGN-3007, PRGN-2009, PRGN-2012, and AG019. In addition, Precigen provides UltraPorator, an electroporation device, and develops research models and services for healthcare research applications. Formerly known as Intrexon Corporation, the company adopted the Precigen name in 2020 and is headquartered in Germantown, Maryland.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PGEN
|
$3.94
|
-27.2% Downside
|
Overvalued
|
$12.45
|
130.1% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 10, 2026
|
-5.0x
|
95.1x
|
60.9x
|
1.808 B
|
1.967 B
|
5.2%
|
53.2%
|
-19.5
|
—
|
30.5%
|
